Pavel Raifeld, Innoviva CEO
February 2, 2022 11:08 AM ESTUpdated 11:24 AM
Deals

Cash-strapped an­tibi­otics play­er En­ta­sis could go pri­vate with a small-dol­lar buy­out of­fer on the ta­ble

Amber Tong

It looks like an­tibi­otics play­er En­ta­sis may be get­ting off Nas­daq the same way it ar­rived — with a whim­per.

En­ta­sis

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times